BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL

BeOne Medicines AG has announced new clinical data and future presentations related to its hematology portfolio, specifically focusing on BRUKINSA® (zanubrutinib) and BGB-16673. At the 67th ASH Annual Meeting and Exposition in Orlando, Florida, the company highlighted long-term efficacy and safety data for BRUKINSA in treatment-naïve chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), demonstrating a 74% progression-free survival $(PFS)$ rate at six years. Additionally, updated results from the ongoing Phase 1/2 CaDAnCe-101 study (NCT05006716) evaluating BGB-16673 monotherapy in patients with B-cell malignancies were shared. These results showed an overall response rate $(ORR)$ of 85.3% across all doses, with an ORR of 94.4% at the recommended phase 2 dose. The study also reported that 54.4% of patients remained on treatment at a median follow-up of 19.8 months. The 12- and 18-month PFS rates were 73.5% and 65.9%, respectively. BeOne Medicines AG stated that additional data from its CLL franchise will be presented at ASH 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208674374) on December 08, 2025, and is solely responsible for the information contained therein.